Tilray

Tilray is a Canadian pharmaceutical and cannabis company, incorporated in the United States with primary operations headquartered in Toronto, Ontario. Tilray also has operations in Australia, New Zealand,[1][2] Germany, Portugal,[3] and Latin America.[4]

Tilray
Public
Traded asNASDAQ: TLRY
IndustryCannabis, Pharmaceutical
Founded2013
FounderBrendan Kennedy
Headquarters
Toronto
,
Canada
Number of employees
750+
WebsiteTilray.com

History

Tilray was founded in 2013. It was originally incorporated under the umbrella of Seattle-based Privateer Holdings. Tilray became the first medical cannabis producer in North America to be GMP certified in December 2016. In July 2018, the company became the first cannabis company to IPO on the NASDAQ and trades under the ticket symbol TLRY.[5] In September 2018, Tilray became the first Canadian cannabis company to legally export medical cannabis to the U.S. for a clinical trial.[6] In December 2018, the company signed a deal with Novartis subsidiary Sandoz to sell, distribute and co-brand Tilray's non-smokeable/non-combustible medical cannabis products in legal markets worldwide.[7] On June 19, 2018, Tilray announced the launch of High Park Company which would operate in the adult recreational cannabis market to establish unique adult-use brands in Canada upon its legalization.[8]

IPO

Tilray made history by being the first cannabis company to debut on a major U.S. stock exchange in July 2018.[9] TLRY debuted on the NASDAQ at a price of $17 per share, and rose dramatically in September 2018 to $214 per share and then crashed to $29 per share by August 2019.[10][11][12][13][14][15]

Global Operations and Exports

Tilray owns and operates global subsidiaries to serve the medical cannabis market in jurisdictions where it is legal and regulated:

  • Tilray Inc. - located in Toronto, Ontario
  • Tilray Deutschland GmbH - located in Berlin, Germany
  • Tilray Portugal Unipessoal, Lda., located in Cantanhede, Portugal is $22.29 million facility including indoor, outdoor and greenhouse cultivation sites, in addition to research labs, processing, packaging and stribution sites for medical cannabis. The EU campus has a GMP certification[16] and covers 5.9 acres.[17]
  • Tilray Australia New Zealand Pty. Ltd. - located in Sydney, Australia
  • High Park Farms, Ltd., located in Enniskillen, Ontario is a wholly owned subsidiary of Tilray Inc, cultivating cannabis primarily for the adult-use market in Canada.[18]
  • High Park Holdings Ltd., located in London, Ontario is a wholly owned subsidiary of Tilray Inc, is a processing, distribution and research affiliate of High Park Farms and High Park Company.[19]

Strategic Partnerships & Acquisitions

In 2018, Tilray announced it had entered into global alliance with Sandoz, a division of Novartis to co-brand and distribute non-combustible medical cannabis products in global markets where it is legally authorized. The Globe and Mail dubbed this partnership as ‘big-pharma’s first foray into cannabis’.[20] 

Also in 2018, Tilray announced a $100-million joint venture with the world's largest brewer, AbInBev to research non-alcohol Tetrahydrocannabinol (THC) and Cannabidiol (CBD)-infused beverages, through their respective subsidiaries Labatt Breweries and High Park Company.[21]

In 2019, Tilray signed a creative $250-million revenue-sharing deal with U.S. based brand company Authentic Brands Group. The partnership will see Tilray leveraging some of ABG's biggest brand names like, Juicy Couture, Greg Norman and Nine West to create cannabis products, powered exclusively by Tilray.  ABG has a portfolio of over 50 brands.[22]

In February 2019, Tilray acquired[23] Manitoba Harvest, the world's largest hemp foods manufacturer, for $317 million from Compass Diversified Holdings. The acquisition allowed Tilray to use Manitoba Harvest's retail distribution network to enter[24] the U.S. CBD market. Manitoba Harvest's products are available in approximately 13,000 U.S. stores and 3,600 in Canada.[23]

Also in 2019, Tilray entered into an agreement with Natura Naturals Holdings which owns 155,000 square feet of licensed cultivation greenhouses in Leamington, Ontario.[25] The acquisition doubled the cultivation ability of the company in Canada.[26] In May 2020, Tilray announced closure of the High Park Gardens site (previously Natura Naturals) in order to pursue cost reduction.[27]

In July 2019, Tilray acquired[28] U.K.-based Smith & Sinclair to develop CBD-infused edibles[28], giving Tilray another way to differentiate itself in the CBD market. In August 2019, Tilray acquired Alberta cannabis retailer Four20[29].

Clinical Trials

In partnership with University of Sydney, NSW Government, Chris O’Brien Lifehouse, Tilray participated in a clinical trial testing the efficacy and tolerability of medical cannabis as treatment for chemotherapy induced nausea & vomiting.[30]

Led by The Hospital for Sick Children, in Toronto, Canada, Tilray provided 2:100, the highest concentration of Cannabidiol (CBD) available in Canada, to test the efficacy and tolerability of medical cannabis oil as treatment for pediatric epilepsy/dravet syndrome. The study showed favourable results.[31][32][33][34]

In partnership with the University of British Columbia, Tilray provided medical cannabis products used to test medical cannabis as treatment for post-traumatic stress disorder.[35]

In partnership with the Grupo Español de Investigación en Neurooncología GEINO, in Spain, Tilray supplied medical cannabis products for the trial testing the efficacy and tolerability of medical cannabis as treatment for glioblastoma.[36]

In August 2019, Tilray announced a partnership with New York University and shipped CBD to the school so that researchers could study its potential ability to treat alcohol use disorder and post-traumatic stress disorder. [37] In the same month, Tilray signed an agreement with Cannamedical Pharma GmbH to export $3.3 million worth of medical cannabis from its Portugal facility to German patients, marking Tilray's first export from Tilray Portugal Unipessoal, Lda.[38]

In partnership with New York University, Tilray imported medical cannabis to the U.S. in October 2019 to support a clinical trial studying its efficacy in treating disorders caused by breast cancer treatments. In December of the same year, Tilray announced a research partnership[39] with Coimbra University in Portugal.

References
  1. SmallCapPower (8 August 2018). "Tilray Stands Out with its Global Supply Agreements".
  2. October 2, Published; 2017 (2 October 2017). "Tilray exports medical cannabis to New Zealand for national dispersal". Marijuana Business Daily.CS1 maint: numeric names: authors list (link)
  3. Commodities; Agriculture (7 September 2017). "Tilray to build $30 million EU cannabis production operation in Portugal - Financial Post".
  4. Schultz, SA Editor Clark (3 December 2018). "Tilray sets up Latin American subsidiary". Seeking Alpha.
  5. "Public shareholders got high today on Tilray, the first marijuana company to IPO on Nasdaq". TechCrunch. Retrieved 2018-09-20.
  6. "Canadian producer Tilray to export medical cannabis to U.S. for clinical trial - Globalnews.ca". globalnews.ca. 18 September 2018.
  7. Borchard D (Dec. 2018). "Tilray Signs Deal With Big Pharma Company Sandoz". Green Market Report. Retrieved 2018-12-18.
  8. "Tilray Launches High Park Company to Produce and Distribute Adult-Use Cannabis in Canada". www.tilray.ca. Retrieved 2019-01-18.
  9. Cherney, Max A. "Tilray IPO: Five things to know about the first pot company to go public on Nasdaq". MarketWatch.
  10. Speights, Keith (2018-09-19). "It's Time for a Reality Check About Tilray -- The Motley Fool". The Motley Fool. Retrieved 2018-09-19.
  11. "Tilray shows the highs, lows of investing in pot". Retrieved 2018-09-19.
  12. "How the Canadian cannabis company Tilray became worth more than American Airlines". Vox. Retrieved 2018-09-19.
  13. Stewart, Emily (19 September 2018). "How the Canadian cannabis company Tilray became worth more than American Airlines". Vox.
  14. https://www.barchart.com/stocks/quotes/TLRY/interactive-chart
  15. "The Marijuana Billionaire Who Doesn't Smoke Weed". Fortune.
  16. Releases, Business Wire News (2019-12-11). "Tilray® Receives Additional GMP Certification at EU Campus Allowing for International Export of Finished Medical Cannabis Products | Financial Post". Retrieved 2020-01-19.
  17. "Sunny Portugal: A gateway to Europe's medical pot market". Reuters. 2019-04-25. Retrieved 2019-08-06.
  18. Phair, John (May 24, 2018). "Rural cannabis facility transforming community". Chatham This Week.
  19. Daniszewski, Hank (5 April 2018). "Now edging into London's manufacturing sector: Marijuana processing". The London Free Press.
  20. Cannabis (2018-03-19). "Big Pharma's first foray into cannabis arrives with Sandoz-Tilray deal | Financial Post". Retrieved 2019-02-12.
  21. "Brewer AB InBev partners with Tilray to tap cannabis drink market". Reuters. 2018-12-19. Retrieved 2019-02-12.
  22. Cannabis (2019-01-15). "Tilray signs creative $250-million revenue-sharing deal with U.S. brand powerhouse ABG | Financial Post". Retrieved 2019-02-12.
  23. Kaiserman, Beth. "Tilray Eyes CBD Food And Drink Market With Manitoba Harvest Acquisition". Forbes. Retrieved 2019-07-26.
  24. Israel, Solomon (2019-05-31). "Manitoba Harvest enters 'wild, wild west' CBD market in U.S." Winnipeg Free Press. Retrieved 2019-07-26.
  25. "Tilray® to Acquire Natura Naturals Holdings Inc. for up to C$70 Million Subject to Performance Milestones". Tilray. Retrieved 2019-02-27.
  26. "Tilray to buy Natura for up to $70M, doubling Canadian cannabis growing capacity | CTV News". www.ctvnews.ca. Retrieved 2019-04-01.
  27. "High Park Gardens Licensed Cannabis Greenhouse In Leamington To Close | windsoriteDOTcaNews". windsorite.ca. Retrieved 2020-07-28.
  28. LaVito, Angelica (2019-07-23). "Tilray acquires boozy candy company Smith & Sinclair to develop CBD edibles". CNBC. Retrieved 2019-07-26.
  29. Press, The Canadian (2019-08-29). "Tilray signs deal to acquire Alberta cannabis retailer Four20 - BNN Bloomberg". BNN. Retrieved 2020-01-19.
  30. "Medicinal Cannabis Factsheet" (PDF).
  31. "First Canadian paediatric study of mixed THC/CBD cannabis oil shows promise for children with drug-resistant epilepsy". SickKids. The Hospital for Sick Children. Retrieved 2019-02-12.
  32. Ubelacker, Sheryl (November 29, 2016). "SickKids to study oral cannabis treatment in kids with severe epilepsy". The Globe and Mail. Retrieved 2019-02-13.
  33. "Tilray introduces new high-CBD extract". www.tilray.ca. Retrieved 2019-02-13.
  34. Carter, Adam (August 1, 2018). "'It's life changing': Mom credits new cannabis oil study with helping daughter's epilepsy". CBC. Retrieved 2019-02-13.
  35. "UBC & Tilray Launch Clinical Trial to Study Medical Cannabis & PTSD - Business Examiner". www.businessexaminer.ca. Retrieved 2019-02-13.
  36. "Tilray CEO talks about medicinal marijuana company's future in Nanaimo and globally". Nanaimo News Bulletin. 2018-07-20. Retrieved 2019-02-13.
  37. LaVito, Angelica (2019-08-08). "Canadian pot company Tilray ships CBD to US for clinical trials on alcohol and PTSD". CNBC. Retrieved 2019-08-08.
  38. Cherney, Max A. "Tilray signs first deal to supply pot to Europe out of new Portugal facility". MarketWatch. Retrieved 2019-08-21.
  39. Freeman, Daphne (2019-12-19). "Tilray partners with Coimbra University to study medical cannabis". Born2Invest. Retrieved 2020-01-19.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.